Centene Corporation (NYSE:CNC) Accelerates Cost Cuts While Positioning For Membership Recovery

Centene shows a mixed near-term technical picture and fundamentally stronger cash generation despite margin pressure; recent workforce cost actions and governance moves sharpen the company’s operational reset. Expect liquidity and free-cash strength to underpin valuation while margins adjust to membership dynamics.

Recent News

On June 16, 2026 Centene announced voluntary separation offers and buyouts to large portions of its workforce as the insurer responds to declines in health plan membership and seeks cost reductions.

On June 19, 2026 the Board expanded to 10 members with the immediate appointment of Lauren M. Tyler, who will serve on audit and compensation/talent committees.

Investment banks updated coverage in late June, including an initiation at sector‑perform/rating adjustments that accompanied analyst commentary on enrollment and cost trends.

Technical Analysis

Directional Indicators (ADX / DI+ / DI-): ADX at 27.81 signals a meaningful trend strength. DI+ shows a dip-and-reverse (now increasing), and DI- shows a peak-and-reverse (now decreasing); together these directional moves favor a bullish directional bias for price action in the near term.

MACD: MACD at 0.11 with a signal line at 0.37 has recently completed a dip-and-reverse; momentum has begun to recover but MACD remains below its signal line, so bullish momentum has started but lacks a confirmed MACD crossover.

MRO (Momentum/Regression Oscillator): MRO at 14.56 (dip-and-reverse) indicates the market price sits above the model target and carries moderate short-term mean-reversion potential, implying upside momentum could encounter corrective pressure.

RSI and Price Positioning: RSI at 55.8 with a dip-and-reverse reads as neutral-to-bullish momentum. Price closed at $66.99, above the 200‑day average of $47.03 and flirting with the upper Bollinger band (upper 1σ $66.56), which suggests near-term upside remains but with limited immediate breadth for extended moves without a momentum confirmation.

Moving Averages & Cloud: Short-term EMAs (12/26) show dip-and-reverse behavior and price sits above the 20‑ and 50‑day averages; Ichimoku components (Tenkan 62.52 / Kijun 63.02 / Senkou A 62.44) support a near-term bullish tilt while volatility measures remain low (42‑day volatility 2%).

 


Fundamental Analysis

Profitability & Margins: EBIT equals $1,639,000,000 and EBIT margin stands at 3.06%, down QoQ by 32.49% and down YoY by 18.19%. That EBIT margin sits below the industry peer mean of 8.33% and below the industry peer median of 4.56%, indicating margin compression relative to peers.

Revenue And Growth: Total revenue reached $53,579,000,000 with YoY revenue growth of 59.89% and QoQ growth of 15.54%, showing strong top-line expansion that reflects scale and enrollment mix shifts even as margins contract.

Cash Flow And Liquidity: Operating cash flow $3,590,000,000 and free cash flow $3,416,000,000 produce a free cash flow yield of 11.49%, which lies well above the industry peer mean of about 1.34%, supporting balance‑sheet flexibility. Cash and short‑term investments total $27,057,000,000 and the cash ratio sits at 0.66, while the current ratio reads 1.15, together signaling ample near‑term liquidity to execute cost adjustments.

Leverage And Coverage: Total debt equals $16,105,000,000 with debt-to-equity 0.71 and debt-to-EBITDA 8.31. Interest coverage equals 10.71x, which supports servicing cost even as debt leverage by EBITDA appears elevated versus typical conservative thresholds.

Returns: Return on equity stands at 4.84% and return on assets at 1.33%; ROE lies above the industry peer mean provided, reflecting that profitability on equity remains positive despite margin pressure.

Earnings Signal: Reported EPS of $2.51 exceeded the $1.08 estimate by $1.43, an EPS surprise of approximately +132.41%, reflecting better-than-expected per‑share results in the reported period; treat that gain in the context of margin volatility and membership-driven operating changes.

Valuation: Price-to-earnings ratio equals 23.97 while forward P/E reads 42.33. Price-to-sales equals 0.55 and enterprise multiple near 9.68. The current valuation as determined by WMDST rates the stock as under-valued; high free cash flow yield and large cash balances justify a valuation premium relative to headline margin metrics, while elevated debt-to-EBITDA moderates that view.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2026-06-30
REPORT DATE: 2026-07-28
NEXT REPORT DATE: 2026-10-27
CASH FLOW  Begin Period Cash Flow 21.4 B
 Operating Cash Flow 3.6 B
 Capital Expenditures -174.00 M
 Change In Working Capital 2.1 B
 Dividends Paid
 Cash Flow Delta 2.9 B
 End Period Cash Flow 24.3 B
 
INCOME STATEMENT REVENUE
 Total Revenue 53.6 B
 Forward Revenue 8.0 B
COSTS
 Cost Of Revenue 49.0 B
 Depreciation 139.0 M
 Depreciation and Amortization 300.0 M
 Research and Development
 Total Operating Expenses 52.4 B
PROFITABILITY
 Gross Profit 4.6 B
 EBITDA 1.9 B
 EBIT 1.6 B
 Operating Income 1.2 B
 Interest Income
 Interest Expense 153.0 M
 Net Interest Income -153.00 M
 Income Before Tax 1.5 B
 Tax Provision 399.0 M
 Tax Rate 26.9 %
 Net Income 1.1 B
 Net Income From Continuing Operations 1.1 B
EARNINGS
 EPS Estimate 1.08
 EPS Actual 2.51
 EPS Difference 1.43
 EPS Surprise 132.407 %
 Forward EPS 1.31
 
BALANCE SHEET ASSETS
 Total Assets 83.0 B
 Intangible Assets 15.0 B
 Net Tangible Assets 7.5 B
 Total Current Assets 46.7 B
 Cash and Short-Term Investments 27.1 B
 Cash 24.2 B
 Net Receivables 18.1 B
 Inventory
 Long-Term Investments 2.9 B
LIABILITIES
 Accounts Payable 18.0 B
 Short-Term Debt 75.0 M
 Total Current Liabilities 40.8 B
 Net Debt
 Total Debt 16.1 B
 Total Liabilities 60.4 B
EQUITY
 Total Equity 22.6 B
 Retained Earnings 11.3 B
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 45.67
 Shares Outstanding 493.987 M
 Revenue Per-Share 108.46
VALUATION
 Market Capitalization 29.7 B
 Enterprise Value 18.8 B
 Enterprise Multiple 9.682
Enterprise Multiple QoQ 113.768 %
Enterprise Multiple YoY -87.636 %
Enterprise Multiple IPRWA high: 75.205
median: 34.394
mean: 34.224
low: 14.996
CNC: 9.682
 EV/R 0.35
CAPITAL STRUCTURE
 Asset To Equity 3.679
 Asset To Liability 1.375
 Debt To Capital 0.417
 Debt To Assets 0.194
Debt To Assets QoQ -3.803 %
Debt To Assets YoY -4.64 %
Debt To Assets IPRWA high: 0.838
mean: 0.417
median: 0.249
low: 0.203
CNC: 0.194
 Debt To Equity 0.714
Debt To Equity QoQ -6.574 %
Debt To Equity YoY 11.296 %
Debt To Equity IPRWA high: 2.844
CNC: 0.714
median: 0.692
mean: -2.028
low: -17.523
PRICE-BASED VALUATION
 Price To Book (P/B) 1.318
Price To Book QoQ 48.748 %
Price To Book YoY 105.646 %
Price To Book IPRWA high: 4.088
median: 1.767
CNC: 1.318
mean: -2.015
low: -13.296
 Price To Earnings (P/E) 23.974
Price To Earnings QoQ 109.344 %
Price To Earnings YoY -126.209 %
Price To Earnings IPRWA high: 133.945
mean: 51.587
median: 50.158
CNC: 23.974
low: -16.66
 PE/G Ratio -0.939
 Price To Sales (P/S) 0.555
Price To Sales QoQ 46.0 %
Price To Sales YoY 54.013 %
Price To Sales IPRWA high: 6.93
mean: 2.42
median: 1.655
CNC: 0.555
low: 0.158
FORWARD MULTIPLES
Forward P/E 42.333
Forward PE/G -1.659
Forward P/S 3.755
EFFICIENCY OPERATIONAL
 Operating Leverage -3.789
ASSET & SALES
 Asset Turnover Ratio 0.653
Asset Turnover Ratio QoQ 3.186 %
Asset Turnover Ratio YoY 16.117 %
Asset Turnover Ratio IPRWA high: 1.051
CNC: 0.653
mean: 0.426
median: 0.4
low: 0.156
 Receivables Turnover 2.857
Receivables Turnover Ratio QoQ 7.361 %
Receivables Turnover Ratio YoY 28.935 %
Receivables Turnover Ratio IPRWA high: 7.49
mean: 3.354
CNC: 2.857
median: 2.487
low: 1.319
 Inventory Turnover
Inventory Turnover Ratio QoQ
Inventory Turnover Ratio YoY
Inventory Turnover Ratio IPRWA
 Days Sales Outstanding (DSO) 31.935
CASH CYCLE
 Cash Conversion Cycle Days (CCC) -3.834
Cash Conversion Cycle Days QoQ -178.591 %
Cash Conversion Cycle Days YoY
Cash Conversion Cycle Days IPRWA high: 41.543
median: 20.353
mean: 9.859
CNC: -3.834
low: -56.959
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 9.041
 CapEx To Revenue -0.003
 CapEx To Depreciation -1.252
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 38.6 B
 Net Invested Capital 38.7 B
 Invested Capital 38.7 B
 Net Tangible Assets 7.5 B
 Net Working Capital 5.9 B
LIQUIDITY
 Cash Ratio 0.664
 Current Ratio 1.145
Current Ratio QoQ 1.952 %
Current Ratio YoY 4.322 %
Current Ratio IPRWA high: 1.698
CNC: 1.145
mean: 1.07
median: 0.993
low: 0.846
 Quick Ratio
Quick Ratio QoQ
Quick Ratio YoY
Quick Ratio IPRWA
COVERAGE & LEVERAGE
 Debt To EBITDA 8.306
 Cost Of Debt 0.689 %
 Interest Coverage Ratio 10.712
Interest Coverage Ratio QoQ -22.367 %
Interest Coverage Ratio YoY -2193.251 %
Interest Coverage Ratio IPRWA CNC: 10.712
high: 9.848
median: 6.321
mean: 6.033
low: 1.576
 Operating Cash Flow Ratio 0.095
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 35.768
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 2.263 %
 Revenue Growth 7.278 %
Revenue Growth QoQ 1554.091 %
Revenue Growth YoY 59.886 %
Revenue Growth IPRWA high: 8.131 %
CNC: 7.278 %
median: 4.497 %
mean: 3.647 %
low: -4.722 %
 Earnings Growth -25.519 %
Earnings Growth QoQ -93.34 %
Earnings Growth YoY -78.298 %
Earnings Growth IPRWA high: 26.971 %
median: -0.128 %
mean: -11.332 %
CNC: -25.519 %
low: -60.417 %
MARGINS
 Gross Margin 8.587 %
Gross Margin QoQ -22.834 %
Gross Margin YoY 42.028 %
Gross Margin IPRWA high: 96.512 %
median: 32.697 %
mean: 31.309 %
CNC: 8.587 %
low: 8.543 %
 EBIT Margin 3.059 %
EBIT Margin QoQ -32.487 %
EBIT Margin YoY -1818.539 %
EBIT Margin IPRWA high: 25.559 %
mean: 8.331 %
median: 4.559 %
CNC: 3.059 %
low: 1.333 %
 Return On Sales (ROS) 2.236 %
Return On Sales QoQ -39.989 %
Return On Sales YoY -370.375 %
Return On Sales IPRWA high: 23.787 %
median: 15.161 %
mean: 10.449 %
CNC: 2.236 %
low: 1.333 %
CASH FLOW
 Free Cash Flow (FCF) 3.4 B
 Free Cash Flow Yield 11.492 %
Free Cash Flow Yield QoQ -47.647 %
Free Cash Flow Yield YoY 27.945 %
Free Cash Flow Yield IPRWA CNC: 11.492 %
high: 5.103 %
mean: 1.337 %
median: 1.25 %
low: -3.081 %
 Free Cash Growth -18.003 %
Free Cash Growth QoQ -101.023 %
Free Cash Growth YoY -222.544 %
Free Cash Growth IPRWA high: 84.175 %
CNC: -18.003 %
median: -60.312 %
mean: -60.897 %
low: -921.619 %
 Free Cash To Net Income 3.131
 Cash Flow Margin 7.23 %
 Cash Flow To Earnings 3.551
VALUE & RETURNS
 Economic Value Added 0.03
 Return On Assets (ROA) 1.329 %
Return On Assets QoQ -31.916 %
Return On Assets YoY -555.137 %
Return On Assets IPRWA high: 2.878 %
mean: 1.636 %
CNC: 1.329 %
median: 1.234 %
low: 0.197 %
 Return On Capital Employed (ROCE) 3.879 %
 Return On Equity (ROE) 0.048
Return On Equity QoQ -32.759 %
Return On Equity YoY -623.944 %
Return On Equity IPRWA high: 0.177
CNC: 0.048
median: 0.033
mean: -0.046
low: -0.347
 DuPont ROE 4.96 %
 Return On Invested Capital (ROIC) 3.099 %
Return On Invested Capital QoQ -29.408 %
Return On Invested Capital YoY -2125.49 %
Return On Invested Capital IPRWA high: 6.906 %
mean: 3.628 %
CNC: 3.099 %
median: 2.914 %
low: 0.822 %

Six-Week Outlook

Near-term technicals favor a constructive bias: directional indicators and moving averages point to upside potential, but MACD remains below its signal line and MRO signals moderate mean-reversion risk. Given solid free cash flow yield and substantial cash balances, expect price action to remain supported on pullbacks while upside requires confirmation via a MACD crossover or a sustained move above the upper Bollinger band. Monitor operational headlines on membership trends and workforce actions for catalysts that could re‑rate margin expectations and shift the medium-term price range.

About Centene Corporation

Centene Corporation (NYSE:CNC) delivers comprehensive healthcare services, primarily targeting under-insured and uninsured populations across the United States. Established in 1984 and based in St. Louis, Missouri, Centene develops a wide array of health plans through its Medicaid, Medicare, and Commercial segments. The Medicaid segment offers expanded health plans, children’s health insurance programs, and long-term services. In the Medicare segment, Centene addresses the needs of seniors with special needs plans, Medicare supplements, and prescription drug plans. The Commercial segment provides marketplace insurance products for individuals and businesses, ensuring extensive access to healthcare services. Centene actively participates in government healthcare contracts, including the TRICARE program for military families, highlighting its dedication to diverse communities. The company also manages clinical healthcare services, pharmacies, and provides dental and speech therapy, promoting a holistic healthcare approach. By collaborating with primary and specialty care physicians, hospitals, and ancillary providers, Centene aims to deliver personalized, high-quality care to millions of Americans, emphasizing innovation and community well-being.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.